FTXH Fact Sheet: First Trust Nasdaq Pharmaceuticals ETF
Share
$43.04
close, Nov 18, 2026
Over the year to Nov 18, 2026, FTXH returned +36.1% in total and charged 0.60% a year.
- 1-year total return
- +36.1%
- to Nov 18, 2026
- Expense ratio
- 0.60%
- a year
- Net assets
- $1.1bn
- on Nov 17, 2026
- Net flow, last 5 trading days
- −$85.5m
- daily basis to Nov 17, 2026
Growth of $10,000, 1 year
FTXH $13,607 +36.1% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.
Returns
WindowTotal return
1 month+3.5%
3 months+1.1%
Year to date+31.2%
1 year+36.1%
3 years+83.1%
5 years+74.0%
Total return, distributions reinvested, each window to Nov 18, 2026.
Ten largest positions
HoldingWeight
Eli Lilly and Company8.35%
AbbVie Inc.7.79%
Johnson & Johnson7.15%
Pfizer Inc.6.82%
Merck & Co., Inc.6.62%
Viatris Inc.4.23%
Regeneron Pharmaceuticals, Inc.4.09%
Gilead Sciences, Inc.3.97%
Biogen Inc.3.95%
Zoetis Inc.3.69%
FTXH top ten by weight, 56.7% of the fund, of its 50 equity positions, from the holdings published by its issuer for Nov 17, 2026.
Facts
Equity fund · Tracks the Nasdaq US Smart Pharmaceuticals Index · First traded Sep 22, 2016 · Benchmark Its own holdings, as of Nov 17, 2026